Blood Product Administration During the Role 1 Phase of Care: The Prehospital Trauma Registry Experience.


Journal

Military medicine
ISSN: 1930-613X
Titre abrégé: Mil Med
Pays: England
ID NLM: 2984771R

Informations de publication

Date de publication:
04 01 2022
Historique:
received: 03 09 2020
revised: 30 11 2020
accepted: 14 12 2020
pubmed: 29 12 2020
medline: 22 3 2022
entrez: 28 12 2020
Statut: ppublish

Résumé

The majority of combat deaths occur in the prehospital setting. Efforts to increase survival including blood transfusions are made in the prehospital setting. The blood products available in the Role 1 setting include whole blood (WB), red blood cells (RBCs), fresh frozen plasma (FFP), and lyophilized (freeze-dried) plasma (FDP). This is a secondary analysis of a previously published dataset within the Prehospital Trauma Registry (PHTR) from 2003 through May 2019. Deterministic linking was used when possible with the DoD Trauma Registry for outcome data. Descriptive statistics were used to analyze the data. We identified 1,357 patient encounters in the PHTR. Within that group, 28 patients received a prehospital blood product, with 41 total administrations: WB (18), RBCs (12), FFP (6), FDP (3), and blood not otherwise specified (2). Outcome data were available for 17 of the 28 patients. The median injury severity score was 20, with the thorax being the most frequent seriously injured body region. Most (94%) patients survived to discharge. The median ICU days was 11 (Interquartile Range [IQR] 3-19), and the median hospital days was 19 (IQR 8-29). The average volume (units) of RBCs was 6.0 (95% CI 1.9-10.1), WB 2.8 (95% CI 0.0-5.6), platelets 0.7 (95% CI 0.0-1.4), and FFP 5.0 (95% CI 1.2-8.8). The use of prehospital blood products is uncommon in U.S. combat settings. Patients who received blood products sustained severe injuries but had a high survival rate. Given the infrequent but critical use and potentially increased need for adequate prolonged casualty care in future near-peer conflicts, optimizing logistical chain circulation is required.

Sections du résumé

BACKGROUND
The majority of combat deaths occur in the prehospital setting. Efforts to increase survival including blood transfusions are made in the prehospital setting. The blood products available in the Role 1 setting include whole blood (WB), red blood cells (RBCs), fresh frozen plasma (FFP), and lyophilized (freeze-dried) plasma (FDP).
METHODS
This is a secondary analysis of a previously published dataset within the Prehospital Trauma Registry (PHTR) from 2003 through May 2019. Deterministic linking was used when possible with the DoD Trauma Registry for outcome data. Descriptive statistics were used to analyze the data.
RESULTS
We identified 1,357 patient encounters in the PHTR. Within that group, 28 patients received a prehospital blood product, with 41 total administrations: WB (18), RBCs (12), FFP (6), FDP (3), and blood not otherwise specified (2). Outcome data were available for 17 of the 28 patients. The median injury severity score was 20, with the thorax being the most frequent seriously injured body region. Most (94%) patients survived to discharge. The median ICU days was 11 (Interquartile Range [IQR] 3-19), and the median hospital days was 19 (IQR 8-29). The average volume (units) of RBCs was 6.0 (95% CI 1.9-10.1), WB 2.8 (95% CI 0.0-5.6), platelets 0.7 (95% CI 0.0-1.4), and FFP 5.0 (95% CI 1.2-8.8).
CONCLUSIONS
The use of prehospital blood products is uncommon in U.S. combat settings. Patients who received blood products sustained severe injuries but had a high survival rate. Given the infrequent but critical use and potentially increased need for adequate prolonged casualty care in future near-peer conflicts, optimizing logistical chain circulation is required.

Identifiants

pubmed: 33367697
pii: 6046689
doi: 10.1093/milmed/usaa563
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e70-e75

Informations de copyright

Published by Oxford University Press on behalf of the Association of Military Surgeons of the United States 2020. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Auteurs

Andrew D Fisher (AD)

Medical Command, Texas Army National Guard, Austin, TX 78763, USA.
Department of Surgery, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA.

Matthew W Paulson (MW)

University of Colorado School of Medicine, Aurora, CO 80045, USA.
CU Anschutz Center for COMBAT Research, Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA.

Jerome T McKay (JT)

CU Anschutz Center for COMBAT Research, Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA.

James Bynum (J)

United States Army Institute of Surgical Research, JBSA Fort Sam Houston, San Antonio, TX 78234, USA.

Kathleen M Flarity (KM)

CU Anschutz Center for COMBAT Research, Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Air Mobility Command, Mobilization Assistant to the Command Surgeon, Scott Air Force Base, Scott AFB, IL, USA.

Michelle Howell (M)

CU Anschutz Center for COMBAT Research, Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA.

Vikhyat S Bebarta (VS)

CU Anschutz Center for COMBAT Research, Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.

Steven G Schauer (SG)

United States Army Institute of Surgical Research, JBSA Fort Sam Houston, San Antonio, TX 78234, USA.
Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
59th Medical Wing, JBSA Lackland, San Antonio, TX 78150, USA.
Department of Emergency Medicine, Brooke Army Medical Center, Fort Sam Houston, TX 78236, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH